Skip to main content

Opko, Bristol-Myers Collaboration to Include Alzheimer's Biomarkers

NEW YORK (GenomeWeb News) – Opko Health said today that it has expanded a collaboration with Bristol-Myers Squibb to include biomarker discovery for pharmacogenomic tests for use in treating Alzheimer's disease.

The Miami-based diagnostics and biopharmaceutical firm said that the deal builds on an earlier partnership aimed at studying the utility of Opko's Alzheimer's diagnostic technologies to now include efforts to identify biomarkers that can predict blood response in several therapeutic areas.

Under the earlier, multi-year collaboration, Opko and BMS have been studying the potential of using Opko's platform for both diagnosing Alzheimer's disease and for identifying individuals with early-stage impairment who may progress to Alzheimer's.

The company's molecular diagnostics platform, which was developed by Scripps Research Institute Professor Thomas Kodadek, uses synthetic molecules called peptoids to screen for autoantibodies in blood that are associated with Alzheimer's disease.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.